BioSpace News Archive

MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced that it will be participating at upcoming conferences.

Sage Therapeutics, Inc., a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced that the U.S. Food and Drug Administration has granted Fast Track Designation to SAGE-718 for development as a potential treatment for Huntington’s disease.

Pulmocide Ltd. (“the Company”), a late-stage biopharmaceutical company focused on the development and commercialization of transformational therapies for patients with severe pulmonary diseases, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug, Fast Track and Qualified Infectious Disease Product designations for opelconazole (PC945) for the treatment of invasive pulmonary aspergillosis (IPA).

Medical practice is characterized as the science and the specialty of mending as per logical determination of the infection.

According to the report, the global medical laser systems market was valued at ~US$ 2 Bn in 2019 and is projected to expand at a higher CAGR during the forecast period.

The Lung Monitoring Devices market will show rapid growth due to the rise in the number of chronic obstructive pulmonary disease patients, Asthma, TB, Etc, urbanization and growing pollution levels, high prevalence of tobacco smoking and development of advanced technologies.

Biophytis SA announces the recommendation by the Data Monitoring Committee to continue the Phase 2-3 COVA study without any modification of the protocol, after the interim efficacy data were found in the promising zone in the Interim Analysis 2 based on 155 COVID-19 patients hospitalized with respiratory failure.

XNK Therapeutics AB announced that Dr. David Berglund and Dr. Stephen Wooding are proposed to be appointed members of the Board of Directors.

AirPhysio aids in mucus clearance and lung expansion and is suited to 99% of those with respiratory issues, including acute and severe conditions. The relaunched product is drug-free and can be used as a treatment and a preventative measure for asthma, atelectasis bronchiectasis, COPD, emphysema, chronic bronchitis, and cystic fibrosis.

AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, announced the appointment of Lars R. Boesgaard as Chief Financial Officer, effective immediately.